The enhanced sensitivity afforded for the detection of heterogeneous disease foci, as evidenced in the femurs of study mice, could promote clinical detection of disease missed by bone marrow biopsy or by am MR imaging technique that could be based on the previously designed anti‐BCMA targeted MRI contrast agent.[14] Therefore, the current study could pave a path towards clinical translation of this innovative immuno‐nanoPET platform in MM patients and open the door for future therapeutic approaches where the radioisotope 64Cu may be replaced by 67Cu. Here, TNFRSF17 is linked to Miyoshi myopathy.